JPRN-UMIN000011937已完成未知
The evaluation of pharmacokinetic and pharmacodynamic properties of Propiverine Hydrochloride transdermal formulation - Pharmacokinetic and pharmacodynamic evaluation of Propiverine Hydrochloride transdermal formulation
Dept of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine0 个研究点目标入组 10 人开始时间: 2013年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 60years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •having skin problems history of allergy
研究者
相似试验
进行中（未招募）
不适用
Evaluation of blood drug level profile, effect and safety after repeated administration of a slow release formulation of S-38844 in healthy male volunteersEUCTR2010-020197-42-DEInstitut de Recherches Internationales Servier27
尚未招募
不适用
A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanilKCT0007066Inje University Busan Paik Hospital15
已完成
不适用
Assessment of pharmacokinetics and pharmacokinetic drug-drug interaction with ketoconazole of the metabolite S 41015 after single oral unlabelled microdoses of S 41015 and i.v. radiolabelled microdoses of [14C]-S 41015, and pharmacokinetics of S 38844 after single oral unlabelled microdose of S 38844 and i.v. radiolabelled microdose of [14C]-S 38844 in healthy male participantshart- en vaatziektencardiovascular diseasesNL-OMON38625Institut de Recherches Internationales Servier I.R.I.S6
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-EEInstitut de Recherches Internationales Servier125
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-HUInstitut de Recherches Internationales Servier200